LIMITED OFFER
Save 50% on book bundles
Immediately download your ebook while waiting for your print delivery. No promo code needed.
Migraine Pain Management
Current Pharmacological and Non-pharmacological Options
- 1st Edition - October 24, 2024
- Editor: Stephen B. Shrewsbury
- Language: English
- Paperback ISBN:9 7 8 - 0 - 4 4 3 - 2 4 7 0 5 - 7
- eBook ISBN:9 7 8 - 0 - 4 4 3 - 2 4 7 0 4 - 0
Migraine Management: Current Pharmacological and Non-pharmacological Options is a comprehensive guide to established, recent, and ongoing pharmaceuticals and device developme… Read more
Purchase options
Institutional subscription on ScienceDirect
Request a sales quoteMigraine Management: Current Pharmacological and Non-pharmacological Options is a comprehensive guide to established, recent, and ongoing pharmaceuticals and device development projects. The book provides detailed information on the historical developments of migraine pain management, druggable targets, drugs action mechanisms, drugs for acute treatment and preventive care of patients, administration routes, and alternative treatments. This is the ideal reference for academic researchers interested in anti-migraine pharmacology. It will also be a perfect reference for physicians and care professionals involved in the well-being of migraine patients.
- Offers a comprehensive overview of pharmacological and alternative migraine pain treatment options
- Covers the historical developments and current targets for drug development and delivery routes
- Provides insights into comorbidities and their impact in patient compliance to treatment
Pharmaceutical/biotechnology researchers in academic and corporate environments, Research physicians, Neurologists, Headache specialists, Psychiatrists, Pain specialists and OBGYNs caring for women in the reproductive years (when migraine is most frequent), Social scientists, Health plan administrators and Health economists
Part I: Foundations and historical development of migraine pain management
1. Introduction
2. Neuroanatomy and Neurophysiology
3. Historical overview of migraine product development
4. Comorbidities and their impact on therapies
5. Not all Migraine attacks are the same
6. Challenges and Controversies; Pharmacokinetics, Linguistics, Semantics and Statistics
Part II: Druggable targets
7. CGRP
8. PACAP
9. Src family kinases (SFK) in Migraine
10. Delta opioid receptor system
11. Piezo channels in peripheral trigeminal nociception
12. TRP antagonists
Part III: Drugs – Acute Management
13. Simple analgesics and combination oral products
14. Cannabinoids & Phytochemicals
15. Ergots
16. Triptans
17. Beta blocker (timolol) eye drops
18. Lasmiditan (and the ditan class)
19. Gepants
Part IV: Drugs – Prevention
20. TCAs (Tricyclic Antidepresants), SNRIs, Beta blockers, candesartan, flunarizine
21. Antiseizure orals (gabapentin, topiramate)
22. Onabotulinumtoxin
23. Gepants (for prevention)
24. (CGRP) Monocloncal antibodies
Part V: Administration routes
25. Oral Drugs (including SMEDDS)
26. Inhaled - oral & nasal
27. Subcutaneous/IM/Transcutaneous ("Injectables")
28. IV/Infusion
Part VI: Alternative Management
29. The role of digital platforms and smartphone apps
30. Herbal Medicines
31. Phototherapy
32. Neuromodulation
33. Acupuncture (for episodic and chronic migraine)
34. Manual Therapies
35. Nutraceuticals and Diets
36. Mindfulness
Part VII: Summary & conclusion [Shrewsbury]
37. Final Perspectives: oral/non-oral pharmaceuticals; devices; Complimentary practices
1. Introduction
2. Neuroanatomy and Neurophysiology
3. Historical overview of migraine product development
4. Comorbidities and their impact on therapies
5. Not all Migraine attacks are the same
6. Challenges and Controversies; Pharmacokinetics, Linguistics, Semantics and Statistics
Part II: Druggable targets
7. CGRP
8. PACAP
9. Src family kinases (SFK) in Migraine
10. Delta opioid receptor system
11. Piezo channels in peripheral trigeminal nociception
12. TRP antagonists
Part III: Drugs – Acute Management
13. Simple analgesics and combination oral products
14. Cannabinoids & Phytochemicals
15. Ergots
16. Triptans
17. Beta blocker (timolol) eye drops
18. Lasmiditan (and the ditan class)
19. Gepants
Part IV: Drugs – Prevention
20. TCAs (Tricyclic Antidepresants), SNRIs, Beta blockers, candesartan, flunarizine
21. Antiseizure orals (gabapentin, topiramate)
22. Onabotulinumtoxin
23. Gepants (for prevention)
24. (CGRP) Monocloncal antibodies
Part V: Administration routes
25. Oral Drugs (including SMEDDS)
26. Inhaled - oral & nasal
27. Subcutaneous/IM/Transcutaneous ("Injectables")
28. IV/Infusion
Part VI: Alternative Management
29. The role of digital platforms and smartphone apps
30. Herbal Medicines
31. Phototherapy
32. Neuromodulation
33. Acupuncture (for episodic and chronic migraine)
34. Manual Therapies
35. Nutraceuticals and Diets
36. Mindfulness
Part VII: Summary & conclusion [Shrewsbury]
37. Final Perspectives: oral/non-oral pharmaceuticals; devices; Complimentary practices
- No. of pages: 636
- Language: English
- Edition: 1
- Published: October 24, 2024
- Imprint: Academic Press
- Paperback ISBN: 9780443247057
- eBook ISBN: 9780443247040
SS
Stephen B. Shrewsbury
Dr. Stephen Shrewsbury recently left Impel Pharmaceuticals where he served as Chief Medical Officer (CMO) from March 2017 and led the development of Precision Olfactory Delivery of DHE through its clinical program and to FDA approval in September 2021. Formerly Stephen was CMO at MAP Pharmaceuticals where he conducted a successful clinical program for an inhaled version of DHE, but it never got approved due to manufacturing issues. Before MAP he was at Chiron Corporation where he was also on the International Pharmaceutical Aerosol Consortium Board of Science. Before Chiron, Stephen spent 9 years with GlaxoSmithKline (last 2 in the US) having moved into the industry in 1993 after 13 years working in the UK’s National Health Service. He has also been CMO for several other West Coast (US) biotech companies; has numerous patents; written and published a book, over 40 scientific papers and nearly 200 abstracts
Affiliations and expertise
Formerly Impel Pharmaceuticals, USARead Migraine Pain Management on ScienceDirect